A targeted radiation treatment called lutetium-177-PSMA-617, sold under the brand name Pluvicto, is changing the outlook for men with metastatic castration-resistant prostate cancer, a disease stage long considered untreatable. Two large phase 3 trials have now shown that the drug extends survival and delays disease progression, and the FDA has twice cleared it for use, most recently expanding its label so patients can receive it before chemotherapy. The therapy works by homing in on a protein found on prostate cancer cells and delivering a lethal dose of radiation directly to tumors, a mechanism researchers describe as “search and destroy.”
How PSMA-Targeted Radiation Finds and Kills Cancer Cells
Prostate-specific membrane antigen, or PSMA, sits on the surface of most prostate cancer cells in far higher concentrations than on healthy tissue. Lutetium-177-PSMA-617 exploits that difference. The drug is a radioligand therapy: a small molecule that binds to PSMA and carries a radioactive isotope, lutetium-177, which emits beta radiation over a short range. Once injected into the bloodstream, it circulates until it locks onto PSMA-expressing cells, then irradiates them from the inside while largely sparing surrounding organs. Patients must first undergo a PSMA-PET imaging scan to confirm their tumors express enough of the target protein, a requirement built into the FDA label from the start.
That precision matters because metastatic castration-resistant prostate cancer, or mCRPC, has already evolved past standard hormone-blocking drugs and, in many cases, past chemotherapy as well. Conventional treatments at this stage aim to slow growth and manage symptoms rather than eliminate disease. Radioligand therapy offers a different angle of attack: it turns the cancer’s own biology into a homing beacon for radiation, reaching metastases in bone, lymph nodes, and soft tissue that external beam radiation cannot easily cover. Reviews of PSMA biology and targeted imaging have underscored how this antigen can be leveraged for both diagnosis and therapy, helping to define which patients are most likely to benefit from PSMA-directed agents.
The VISION Trial: Survival Gains After Chemotherapy
The evidence that first brought Pluvicto to market came from the VISION trial, a phase 3 randomized study published in The New England Journal of Medicine. VISION enrolled men with PSMA-positive mCRPC whose disease had progressed after at least one androgen receptor pathway inhibitor and one or two lines of taxane chemotherapy. Patients were randomized to receive lutetium-177-PSMA-617 plus protocol-permitted standard of care or standard of care alone. According to the primary publication, the addition of the radioligand significantly improved overall survival and radiographic progression-free survival, establishing the therapy as a new standard for heavily pretreated patients.
Beyond tumor control, VISION collected prespecified data on how patients actually felt during treatment. A companion analysis in The Lancet Oncology reported health-related quality of life outcomes, pain progression endpoints, and symptomatic skeletal event rates. Men receiving the radioligand experienced slower worsening of pain and fewer bone-related complications, outcomes that carry real weight for a population in which skeletal metastases are common and debilitating. Those quality-of-life findings helped distinguish Pluvicto from treatments that extend survival on paper but leave patients struggling with side effects, supporting a more holistic view of benefit.
Regulatory Pathway and Trial Design Details
The VISION study was designed and registered as a pivotal trial, with its protocol publicly available through a clinical trial listing that details eligibility criteria, imaging requirements, and dosing schedules. Men in the trial had to demonstrate PSMA-positive disease on PET imaging and adequate organ function to tolerate repeated infusions of the radioligand. Standard-of-care therapies allowed in the control arm excluded additional chemotherapy or experimental agents, a restriction intended to isolate the effect of lutetium-177-PSMA-617 on key endpoints such as overall survival. Stratification factors, including prior taxane exposure and baseline disease burden, aimed to balance known prognostic variables between the treatment groups.
These design elements fed directly into the regulatory review, which assessed both efficacy and safety in the context of an advanced, heavily pretreated population. The New England Journal of Medicine report emphasized that the survival advantage emerged despite the control arm receiving what investigators considered best available standard care at the time. Together with the trial’s registration data, these findings gave regulators confidence that the observed benefits were robust and clinically meaningful. The structured approach to trial conduct also created a template for subsequent PSMA-targeted studies, including those exploring earlier lines of therapy and different combinations.
FDA Expands Access Before Chemotherapy
The original FDA approval in early 2022 restricted Pluvicto to patients who had already tried both hormone therapy and taxane chemotherapy, a late-in-the-line position that limited the eligible population. That changed when the agency reviewed results from PSMAfore, a separate phase 3 randomized controlled trial published in The Lancet. PSMAfore compared lutetium-177-PSMA-617 against a switch to a different androgen receptor pathway inhibitor in men with taxane-naive mCRPC whose cancer had progressed on a prior hormone therapy. The trial showed meaningful improvement in radiographic progression-free survival for the radioligand arm, suggesting that earlier use of PSMA-targeted radiation can delay disease worsening.
Based on those findings, the FDA expanded Pluvicto’s indication to allow use before chemotherapy, a significant shift that opens the drug to a larger group of patients earlier in their treatment journey. The PSMAfore data also included a high crossover rate, meaning many men originally assigned to the control arm eventually received the radioligand, which complicates interpretation of overall survival differences between the two groups. In its review summary, the agency noted that such crossover likely diluted any measurable survival gap between arms while still supporting the observed delay in progression. Clinicians now must weigh the benefits of earlier radioligand therapy against other available options, considering patient comorbidities, preferences, and access to specialized nuclear medicine facilities.
Safety, Monitoring, and Patient Experience
Like all radiopharmaceuticals, lutetium-177-PSMA-617 carries specific safety considerations related both to radiation exposure and to off-target effects on normal tissues. The most common adverse events in clinical trials included fatigue, dry mouth, nausea, and mild bone marrow suppression, reflecting uptake in salivary glands and bone marrow as well as tumor sites. Patients typically receive the drug as an outpatient intravenous infusion every six weeks, with blood counts and kidney function monitored before each cycle. Safety reporting requirements encourage clinicians and patients to document suspected adverse reactions through established pharmacovigilance systems, helping regulators track rare or delayed toxicities that may not appear in initial trials.
Despite these risks, many men report that radioligand therapy is more tolerable than chemotherapy, with fewer day-to-day disruptions to quality of life. The VISION quality-of-life analysis found that time to deterioration in pain and functional status favored the lutetium-177-PSMA-617 arm, aligning with patient anecdotes of symptom relief as tumor burden decreases. Radiation safety protocols, such as temporary precautions around close contact and bodily fluids, are generally time-limited because lutetium-177 has a relatively short physical half-life. Education about these measures, along with clear communication about expected side effects, allows patients and caregivers to prepare for treatment and participate actively in shared decision-making.
Next-Generation Agents in Early Testing
While Pluvicto is the only approved PSMA-targeted radioligand therapy, the field is not standing still. Researchers at the Institute of Cancer Research reported that a targeted radiotherapy injection shrank treatment-resistant prostate cancer tumors in an early clinical trial, with results presented at the ASCO Genitourinary Cancers Symposium. That work signals a pipeline of newer agents designed to improve on the current drug’s potency, reduce side effects, or reach tumors that express lower levels of PSMA. Some investigational compounds use different radionuclides, including alpha emitters, which deposit more energy over an even shorter range and could potentially overcome resistance in heavily pretreated disease.
Parallel efforts are exploring combinations of PSMA-targeted radioligands with other systemic therapies, such as androgen receptor pathway inhibitors, PARP inhibitors, or immunotherapies, in the hope of achieving deeper and more durable responses. Early-phase studies are also assessing whether radioligand therapy might have a role in earlier stages of prostate cancer, including hormone-sensitive metastatic disease, where tumor burden is lower and patients may have more years of life to gain. As these trials mature, they will test whether the “search and destroy” paradigm that transformed options for late-stage mCRPC can be safely extended to broader populations, potentially reshaping the standard of care across the prostate cancer continuum.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
